“Oligonucleotide Synthesis Market, by Product (Drug, Synthesized Oligos [Primer, Probe], Reagents), Type (Custom, Predesign), Application (Therapeutic [ASO, siRNA], Research [PCR], Diagnostic), End User (Hospital, Pharma, CROs) – Global Forecast to 2026”
MarketsandMarkets: The oligonucleotide synthesis market is projected to reach USD 14.1 billion by 2026 from USD 6.3 billion in 2021, at a CAGR of 17.6?tween 2021 and 2026.
The major factors driving the growth of this market include the increasing use of synthesized oligos in therapeutic applications, increasing government funding, and the growing focus on personalized medicine. Countries such as China, India, Singapore, and emerging economies such as Brazil provide significant growth opportunities for the oligonucleotide synthesis industry. This potential is mainly due to the increasing R&D investments by various leading companies in emerging economies of the Asia Pacific and Latin America regions.
Download PDF Brochure:
The primers segment accounted for the fastest growing segment of the synthesized oligos product segment of the market in 2020.
Based on product, the market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides, reagents, and equipment. By product, the synthesized oligonucleotides market is segmented into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos. In 2020, the primers segment accounted for the fastest growing segment of this market, as they are used in various applications such as PCR, sequencing, gene synthesis, and cloning applications, among others.
The hospital segment accounted for the largest share of the end user segment in the oligonucleotide synthesis market in 2020.
Based on end users, the market is categorized into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, contract manufacturing organizations (CMOs) & contract research organizations (CROs), and academic & government institutes. In 2020, Hospitals accounted for the largest share of the oligonucleotide synthesis industry. Growth in this market is largely driven by the significant number of inpatient & outpatient visits in hospitals and the high requirement of oligonucleotide drugs to cater to the growing demand of patients suffering from rare diseases, neurological disorders, and infectious diseases.
The antisense oligonucleotide-based therapies segment accounted for the largest share of the therapeutic application in 2020.
Based on application, the oligonucleotide synthesis market is segmented into therapeutic, research, and diagnostic applications. The therapeutic application segment is further segmented into Antisense oligonucleotide-based therapies, siRNAi oligonucleotide-based therapies, and CpG oligonucleotide-based therapies. IN 2020, antisense oligos accounted for the largest share of this segment as they form the basis of many therapies that are currently in clinical trials, thus boosting segment growth.
The PCR sub segment accounted for the largest share of the research application segment in the oligonucleotide synthesis market in 2020.
Based on application, the market is segmented into therapeutic, research and diagnostic applications. The research application segment is further segmented into, PCR, sequencing and other research applications. In 2020, PCR sub segment accounted for the largest share of the research application segment in the oligonucleotide synthesis industry. PCR technologies such as qPCR are highly sensitive and cost-effective which drive the market growth for PCR. These PCR applications utilize sequence-specific primers, thus boosting the market for oligos (which are used as probes and primers) in the PCR market.
The Asia Pacific region is the fastest growing region of the oligonucleotide synthesis market in 2020.
In 2020, the Asia Pacific region accounted for the fasted growing region of the oligonucleotide synthesis industry. Factors such as growing R&D funding, rising product availability, lower outsourcing costs, increasing research activities, increasing applications of oligos in molecular diagnostics & therapeutics, and the rising awareness of oligonucleotides are expected to drive market growth.
Request Sample Pages:
Some of the leading players operating in the oligonucleotide synthesis market are Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), and Agilent Technologies, Inc. (US). The leading players in the oligonucleotide therapeutics market are Biogen Inc. (US) and Sarepta Therapeutics, Inc. (US).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities influencing the growth of the oligonucleotide synthesis market. A detailed analysis of the key industry players has been done to provide insights into their business overviews; solutions and services; key strategies; new product launches; product approvals, acquisitions, partnerships, agreements, collaborations; and recent developments associated with the oligonucleotide synthesis industry.